N/A
N=1,769
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Metastatic Renal Cell Carcinoma
Bottom Line
View on ClinicalTrials.gov: NCT04076787 ↗Enrolled (actual)
1,769
Serious AEs
—
Results posted
Oct 2019
Primary outcome: Primary: Overall Survival — 52.1; 31.5; 9.8 months
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Sunitinib (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Sep 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Survival |
52.1; 31.5; 9.8 | — |
| PRIMARY Time to First-Line Sunitinib Treatment Discontinuation |
15.0; 8.5; 4.2 | — |
| PRIMARY Number of Participants Who Discontinued First-Line Sunitinib Treatment |
91; 316; 122; 52; 141; 42 | — |
| PRIMARY Percentage of Participants With Objective Response (OR) |
38.5; 34.6; 21.7 | — |
| PRIMARY Percentage of Participants With Progressive Disease |
16.3; 27.1; 46.0 | — |
| PRIMARY Percentage of Participants With Stable Disease |
45.1; 38.4; 32.3 | — |
Summary
This is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib as first-line treatment.
Eligibility Criteria
Inclusion Criteria
- Diagnosed with mRCC
- Initiated treatment post mRCC diagnosis and received sunitinib as first-line therapy
- Age 18 years or over at the time of mRCC diagnosis
- Actively treated at an IMDC clinical center
Exclusion Criteria
- Initiated first line sunitinib treatment before 2010
- Had non-clear cell mRCC
Data sourced from ClinicalTrials.gov (NCT04076787). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.